SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome
SOTO Study: Prospective Study to Correlate the Treatment Sensitivity of Patient-derived Organoids With Clinical Outcomes in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Anthony Kong
- Phone Number: 0207-848-8302
- Email: anthony.kong@kcl.ac.uk
Study Contact Backup
- Name: Ifigenia Vasiliadou
- Phone Number: 0207-848-8302
- Email: ifigenia.1.vasiliadou@kcl.ac.uk
Study Locations
-
-
-
London, United Kingdom, SE1 9RT
- Recruiting
- Guys Hospital
-
Contact:
- Anthony Kong, Dr
- Email: anthony.kong@kcl.ac.uk
-
Contact:
- Ifigenia ifigenia.1.vasiliadou@kcl.ac.uk, Dr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with head and neck squamous cell carcinoma (including oral cavity, oropharynx, paranasal sinuses, hypopharynx or larynx) undergoing curative treatment (primary surgery or radiotherapy) or presenting with recurrent or metastatic cancers
- Age > 18 years old
Exclusion Criteria:
- Patients unable to give informed consent e.g. mental disability or vulnerable adults
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Cohort 1
Surgically resectable disease, followed by adjuvant radiotherapy +/- chemotherapy
|
|
Cohort 2
Primary radiotherapy +/- concurrent chemotherapy
|
|
Cohort 3
Recurrent or metastatic HNSCC undergoing platinum based chemotherapy +/- cetuximab
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Successful Organoids
Time Frame: 1 Year
|
To assess the percentage of successful generated organoids from tissues in head and neck cancer patients
|
1 Year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity
Time Frame: 1 Year
|
To assess the sensitivity of radiotherapy, platinum (cisplatin and/or carboplatin) chemotherapy or cetuximab or their combination in PDOs
|
1 Year
|
|
Treatment Outcome
Time Frame: 1 Year
|
To correlate the treatment sensitivities of PDOs with the treatment outcome of patients
|
1 Year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment Sensitivities
Time Frame: 1 Year
|
To correlate the treatment sensitivities of PDOs with the detection rates of plasma ctDNA (all cohorts)
|
1 Year
|
|
Patients Features
Time Frame: 1 Year
|
To assess and correlate the histopathological, genomic and transcriptomic features of patients' samples with PDOs
|
1 Year
|
|
PDOs Sensitivities
Time Frame: 1 Year
|
To assess the sensitivities of PDOs to various targeted therapies based on their genomic profiles
|
1 Year
|
|
Translational Research
Time Frame: 1 Year
|
Collection of archival tissues, blood samples (for ctDNA and PBMC), saliva (for ctDNA), urine or stool samples for other translational research
|
1 Year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SOTO Study 305689
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.